Document is current
Any future updates will be listed below
-
Authors
Silva, Rebeca Nunes https://orcid.org/0000-0001-7273-2399
Porszasz, Janos
Ferguson, Carrie
Rehder-Santos, Patrícia
Roscani, Meliza Goi
de Oliveira, Claudio Ricardo
Catai, Aparecida Maria
Stringer, William W.
Borghi-Silva, Audrey https://orcid.org/0000-0002-3891-6941
-
Funding
Funding for this research was provided by:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Fundação de Amparo à Pesquisa do Estado de São Paulo
- License Information
-
More Information
Article History
Received: 6 September 2024
Accepted: 11 July 2025
First Online: 5 August 2025
Declarations
:
: The authors declare no conflicts of interest.
: Rebeca Nunes Silva reports financial support for the present study from Coordination for the Improvement of Higher Educational Personnel (CAPES), Brazil (CAPES 001 – PhD Scholarship; CAPES PrInt – Program #6685). Janos Porszasz receives royalty payments from a CPET book from Wolters Kluwer. Carrie Ferguson is supported by grants from NIH (R01HL166850; 5UH3HL155798). She is involved in contracted clinical research with United Therapeutics, Genentech, Regeneron, Respira Therapeutics and Mezzion. She reports consulting fees from Respira Therapeutics. She is a visiting Associate Professor at the University of Leeds, UK. Patrícia Rehder-Santos has no research funding to declare. Meliza Goi Roscani reports financial support from São Paulo Research Foundation (FAPESP) (Grants #2021/05231–7 and #2023/04876–0). Claudio Ricardo Oliveira has no research funding to declare. Aparecida Maria Catai is supported by the National Council for Scientific and Technological Development (CNPq – level 1A Research Fellow, #310,612/2019–5) and receives financial support from FAPESP (#2016/22215-7). William Stringer is involved in contracted clinical research with Genentech, Regeneron, Roche, AstraZeneca and the NIH Recover-Vital and Recover-Neuro clinical trials. He performs CPET Data Center activities for the NIH funded PETRACT study (UG3HL155798-01A1). He is a co-investigator on an NIH Small Business Innovation Award (1R43HL167289-01) and has been a site PI for the NIH RETHINC (5U01HL128954‐04) and BLOCK-COPD (W81XWH-15–1-0705) studies. He performs Data Safety Monitoring Board activities for SYNEOS and CAPRICOR. He receives royalty payments from a CPET book from Wolters Kluwer. He is a paid consultant for Genentech, Verona and Regeneron. He owns stock in HIA. Audrey Borghi-Silva is involved in research grants from FAPESP (Grant #2015/26/501–1), CAPES-Brazil (CAPES-001), and CNPq-Brazil (Grant #201,157/2024–1) with national and international collaboration. Audrey Borghi-Silva is an established Investigator (level 1B) of CNPq. Currently, she is advisor of the scientific board of FAPESP.
